SCHEMBL5145239

SCHEMBL5145239

COC(=O)c1ccc(-c2ccc(/C=C3\NC(=O)N(c4cccc(Cl)c4)C3=O)o2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 11/20 0.58
MAPT P10636 8/20 0.58
KDM4E B2RXH2 8/20 0.58
KMT2A Q03164 7/20 0.58
POLB P06746 7/20 0.58
RECQL P46063 7/20 0.58
APEX1 P27695 7/20 0.58
MEN1 O00255 6/20 0.58
CTDSP1 Q9GZU7 5/20 0.58
L3MBTL1 Q9Y468 4/20 0.58
PTPN1 P18031 1/20 0.58
ALDH1A1 P00352 8/20 0.54
DNMT1 P26358 2/20 0.53
PSMD14 O00487 2/20 0.53
MMP2 P08253 2/20 0.53
HPGD P15428 2/20 0.53
SIRT2 Q8IXJ6 2/20 0.52
GAA P10253 2/20 0.52
RAB9A P51151 2/20 0.52
HTT P42858 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5145246 1.00 TDP1 (0.58) TDP1MAPTKDM4EKMT2APOLB
SCHEMBL6397402 0.80 KMT2A (0.87) TDP1MAPTKDM4EKMT2APOLB
SCHEMBL6395653 0.80 TDP1 (0.75) TDP1MAPTKDM4EKMT2APOLB
SCHEMBL6395650 0.80 TDP1 (0.75) TDP1MAPTKDM4EKMT2APOLB
SCHEMBL6397406 0.80 KMT2A (0.87) TDP1MAPTKDM4EKMT2APOLB
SCHEMBL6397787 0.79 MAPT (0.62) TDP1MAPTKDM4EKMT2APOLB
SCHEMBL6397790 0.79 MAPT (0.62) TDP1MAPTKDM4EKMT2APOLB
SCHEMBL6395803 0.76 POLB (0.84) TDP1MAPTKDM4EKMT2APOLB
SCHEMBL6395805 0.76 POLB (0.84) TDP1MAPTKDM4EKMT2APOLB
SCHEMBL5163809 0.69 SIRT2 (1.00) TDP1MAPTKMT2APOLBRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1718308-A4 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORP (CA) 2007-07-18 EP disclosed
EP-1718308-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PainCeptor Pharma Corp. (CA) 2006-11-08 EP disclosed
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2005-12-22 US disclosed
WO-2005076695-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2005-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity NGF, BDNF, NTRK2 TDP1 1996/4885MAPT 2096/4885KDM4E 4569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.